- Richard Morgan, Professor of Molecular Oncology, University of Bradford
- Read Time: 6 mins
Patients with prostate cancer in England and Wales will now have early access to abiraterone, a drug which can delay the need for chemotherapy. The drug previously cost £3,000 a month, and was not considered “cost-effective” for the NHS until cancers were more advanced – even though patients in Scotland had access to it.